Understanding how common fatty liver disease is in patients with Type 1 Diabetes
The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium
This study is trying to find out how many people with Type 1 Diabetes also have Nonalcoholic Fatty Liver Disease by using a special scan to check their liver health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 138 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ziekenhuis Oost-Limburg Academic / other |
| Locations | 1 site (Genk, Limburg) |
| Trial ID | NCT06445361 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) among patients diagnosed with Type 1 Diabetes Mellitus (T1DM). It involves the use of a FibroScan, a non-invasive imaging technique, to evaluate liver health in participants. The study will include adults aged 18 and older who provide informed consent, while excluding those with excessive alcohol use or other liver disease causes. The findings could provide valuable insights into the liver health of T1DM patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with a diagnosis of Type 1 Diabetes.
Not a fit: Patients with excessive alcohol use or other causes of liver disease will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of liver health in Type 1 Diabetes patients, potentially leading to better management strategies.
How similar studies have performed: While studies on NAFLD in diabetes exist, this specific focus on T1DM patients is less common, making it a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * T1DM * ≥ 18 years of age * Written informed consent obtained Exclusion Criteria: * Excessive alcohol use * Exclusion of other causes of liver disease and secondary causes of liver steatosis
Where this trial is running
Genk, Limburg
- Ziekenhuis Oost-Limburg — Genk, Limburg, Belgium (Recruiting)
Study contacts
- Study coordinator: Leen Heyens, MsC
- Email: nafldstudie@zol.be
- Phone: 089 21 20 55
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.